Louis Scampavia

3.0k total citations · 1 hit paper
102 papers, 2.1k citations indexed

About

Louis Scampavia is a scholar working on Molecular Biology, Biomedical Engineering and Oncology. According to data from OpenAlex, Louis Scampavia has authored 102 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Molecular Biology, 23 papers in Biomedical Engineering and 14 papers in Oncology. Recurrent topics in Louis Scampavia's work include Receptor Mechanisms and Signaling (14 papers), 3D Printing in Biomedical Research (10 papers) and Microfluidic and Capillary Electrophoresis Applications (10 papers). Louis Scampavia is often cited by papers focused on Receptor Mechanisms and Signaling (14 papers), 3D Printing in Biomedical Research (10 papers) and Microfluidic and Capillary Electrophoresis Applications (10 papers). Louis Scampavia collaborates with scholars based in United States, Germany and China. Louis Scampavia's co-authors include Timothy Spicer, Jaromír Ru̇žička, Franck Madoux, J. Růžička, Peter Hodder, Shurong Hou, Thomas D. Bannister, Emery Smith, Pierre Baillargeon and Dmitriy Minond and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Journal of Neuroscience.

In The Last Decade

Louis Scampavia

96 papers receiving 2.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

LPCAT3 Inhibitors Remodel the Polyunsaturated Phospholipid Content of Human Cells and Protect from Ferroptosis

2022 105 citations Yuka Otsuka, Louis Scampavia et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Louis Scampavia United States	24	864	610	287	264	176	102	2.1k
Sheng Ye China	33	1.9k 2.2×	255 0.4×	331 1.2×	250 0.9×	61 0.3×	120	3.1k
Bettina Sarg Austria	32	2.0k 2.3×	284 0.5×	238 0.8×	224 0.8×	62 0.4×	105	3.1k
Hiroshi Ueda Japan	37	3.7k 4.3×	828 1.4×	309 1.1×	483 1.8×	64 0.4×	296	5.5k
Roman Mezencev United States	29	1.1k 1.3×	474 0.8×	523 1.8×	472 1.8×	32 0.2×	86	2.4k
Pierre Jeannesson France	26	1.3k 1.5×	186 0.3×	179 0.6×	376 1.4×	235 1.3×	79	2.5k
Lijuan Zhang China	29	2.2k 2.6×	426 0.7×	117 0.4×	201 0.8×	63 0.4×	99	3.1k
Osman Uğur Sezerman Türkiye	25	1.4k 1.6×	411 0.7×	97 0.3×	128 0.5×	34 0.2×	158	2.5k
Zhe Jin China	24	685 0.8×	199 0.3×	100 0.3×	259 1.0×	98 0.6×	96	2.4k
Guoquan Yan China	32	2.4k 2.7×	308 0.5×	199 0.7×	309 1.2×	86 0.5×	136	3.4k
King C. Chan United States	34	2.0k 2.3×	899 1.5×	157 0.5×	269 1.0×	127 0.7×	88	3.7k

Countries citing papers authored by Louis Scampavia

Since Specialization

Citations

This map shows the geographic impact of Louis Scampavia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louis Scampavia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louis Scampavia more than expected).

Fields of papers citing papers by Louis Scampavia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louis Scampavia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louis Scampavia. The network helps show where Louis Scampavia may publish in the future.

Co-authorship network of co-authors of Louis Scampavia

This figure shows the co-authorship network connecting the top 25 collaborators of Louis Scampavia. A scholar is included among the top collaborators of Louis Scampavia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louis Scampavia. Louis Scampavia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharma, Nandini, Yuka Otsuka, Louis Scampavia, Timothy Spicer, & Jarrod B. French. (2025). A high throughput assay for phosphoribosylformylglycinamidine synthase. SLAS DISCOVERY. 31. 100212–100212.

Scampavia, Louis, et al.. (2024). Protocol for high throughput 3D drug screening of patient derived melanoma and renal cell carcinoma. SLAS DISCOVERY. 29(3). 100141–100141. 4 indexed citations

Otsuka, Yuka, Eunjung Kim, Chao Wang, et al.. (2024). High throughput screening for SARS-CoV-2 helicase inhibitors. SLAS DISCOVERY. 29(6). 100180–100180. 3 indexed citations

Moghadasi, Seyed Arad, Yuka Otsuka, Christina B. Cooley, et al.. (2024). SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening. SLAS DISCOVERY. 29(6). 100181–100181. 2 indexed citations

Otsuka, Yuka, Simon Lattmann, Chong Wai Liew, et al.. (2024). A high-throughput cell-based screening method for Zika virus protease inhibitor discovery. SLAS DISCOVERY. 29(5). 100164–100164. 2 indexed citations

Smith, Emery, Meredith E. Davis-Gardner, Rubén D. Garcia-Ordoñez, et al.. (2023). High throughput screening for drugs that inhibit 3C-like protease in SARS-CoV-2. SLAS DISCOVERY. 28(3). 95–101. 13 indexed citations

Coant, Nicolas, John D. Bickel, Ronald J. Rahaim, et al.. (2023). Neutral ceramidase-active site inhibitor chemotypes and binding modes. Bioorganic Chemistry. 139. 106747–106747. 1 indexed citations

Fernández-Vega, Virneliz, Jantzen Sperry, Jonathan Nakashima, et al.. (2023). In Vitro and In Vivo Drug-Response Profiling Using Patient-Derived High-Grade Glioma. Cancers. 15(13). 3289–3289. 7 indexed citations

Wang, Chao, HaJeung Park, Christoph Becker‐Pauly, et al.. (2021). Discovery and Optimization of Selective Inhibitors of Meprin α (Part II). Pharmaceuticals. 14(3). 197–197. 4 indexed citations

10.

Qin, Jun, Mafei Xu, Jingjing Shi, et al.. (2020). Small-molecule inhibitor targeting orphan nuclear receptor COUP-TFII for prostate cancer treatment. Science Advances. 6(18). eaaz8031–eaaz8031. 23 indexed citations

11.

Nieto, Ainhoa, Virneliz Fernández-Vega, Timothy Spicer, et al.. (2018). Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119. Assay and Drug Development Technologies. 16(5). 278–288. 5 indexed citations

12.

Muntean, Brian S., Dipak N. Patil, Franck Madoux, et al.. (2018). A High-Throughput Time-Resolved Fluorescence Energy Transfer Assay to Screen for Modulators of RGS7/Gβ5/R7BP Complex. Assay and Drug Development Technologies. 16(3). 150–161. 3 indexed citations

13.

Smith, Emery, Kenneth A. Giuliano, Pierre Baillargeon, et al.. (2017). A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel. Assay and Drug Development Technologies. 15(8). 395–406. 7 indexed citations

14.

Plate, Lars, Christina B. Cooley, John J. Chen, et al.. (2016). Small molecule proteostasis regulators that reprogram the ER to reduce extracellular protein aggregation. eLife. 5. 173 indexed citations

15.

Smith, Emery, Peter Chase, Colleen M. Niswender, et al.. (2015). Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4). SLAS DISCOVERY. 20(7). 858–868. 25 indexed citations

16.

Madoux, Franck, Jo Ann Janovick, David C. Smithson, et al.. (2015). Development of a Phenotypic High-Content Assay to Identify Pharmacoperone Drugs for the Treatment of Primary Hyperoxaluria Type 1 by High-Throughput Screening. Assay and Drug Development Technologies. 13(1). 16–24. 17 indexed citations

17.

Chase, Peter, et al.. (2015). An Automated Miniaturized Method to Perform and Analyze Antimicrobial Drug Synergy Assays. Assay and Drug Development Technologies. 14(1). 58–66. 3 indexed citations

18.

Conn, P. Michael, Emery Smith, Timothy Spicer, et al.. (2014). A Phenotypic High Throughput Screening Assay for the Identification of Pharmacoperones for the Gonadotropin Releasing Hormone Receptor. Assay and Drug Development Technologies. 12(4). 238–246. 13 indexed citations

19.

Kota, Smitha, Louis Scampavia, Timothy Spicer, et al.. (2009). A Time-Resolved Fluorescence–Resonance Energy Transfer Assay for Identifying Inhibitors of Hepatitis C Virus Core Dimerization. Assay and Drug Development Technologies. 8(1). 96–105. 21 indexed citations

20.

Scampavia, Louis, Peter Hodder, Ilkka Lähdesmäki, & Jaromír Ru̇žička. (1999). Automation of functional assays by flow injection fluorescence microscopy. Trends in biotechnology. 17(11). 443–447. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact